1 reports of this reaction
14.3% of all AVOBENZONE, OCTISALATE, OCTOCRYLENE reports
#4 most reported adverse reaction
DYSPHONIA is the #4 most commonly reported adverse reaction for AVOBENZONE, OCTISALATE, OCTOCRYLENE, manufactured by Access Business Group LLC. There are 1 FDA adverse event reports linking AVOBENZONE, OCTISALATE, OCTOCRYLENE to DYSPHONIA. This represents approximately 14.3% of all 7 adverse event reports for this drug.
Patients taking AVOBENZONE, OCTISALATE, OCTOCRYLENE who experience dysphonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPHONIA is a frequently reported adverse event for AVOBENZONE, OCTISALATE, OCTOCRYLENE, accounting for a significant proportion of all reports.
In addition to dysphonia, the following adverse reactions have been reported for AVOBENZONE, OCTISALATE, OCTOCRYLENE:
The following drugs have also been linked to dysphonia in FDA adverse event reports:
DYSPHONIA has been reported as an adverse event in 1 FDA reports for AVOBENZONE, OCTISALATE, OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPHONIA accounts for approximately 14.3% of all adverse event reports for AVOBENZONE, OCTISALATE, OCTOCRYLENE, making it a notable side effect.
If you experience dysphonia while taking AVOBENZONE, OCTISALATE, OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.